Phaseline

Targets › SARS-COV-2

SARS-COV-2: drug programs, companies and trials

3 programs from 3 companies in 11 trials: 5 Phase 3, 3 Phase 4, 2 Phase 2, 1 Phase 1; Infectious disease; next expected readout Apr 2027.

Open in Phaseline: the race on SARS-COV-2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
BioNTech SETozinameran
Spike glycoprotein vaccine antigen
SARS-COV-2Phase 4COVID-19 Vaccines; COVID-19; Diabetes Mellitus, Type 1Apr 2027
NovavaxNVX-CoV2705
Omicron JN.1 subvariant SARS-CoV-2 recombinant spike protein vaccine adjuvanted with Matri
SARS-COV-2Phase 4COVID-19–
Interna TherapeuticsApo-Si-K170A-C76
small interfering RNA (siRNA) against SARS-CoV-2
SARS-COV-2Phase 1SARS-CoV-2 (COVID-19) Infection–

Conditions

COVID-19 (5) COVID-19 Vaccines (4) Diabetes Mellitus, Type 1 (1) SARS-CoV-2 (COVID-19) Infection (1)

Modalities

other (1), small molecule (1), protein or peptide (1)

Companies

BioNTech SE (1) Interna Therapeutics (1) Novavax (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.